Andrew JM Boulton, MD, DSc, FICP, FACP, FRCP
Professor of Medicine, Faculty of Biology, Medicine and Health, University of Manchester. Manchester, UK.
Professor of Medicine, Athens University Medical School First Department of Pediatrics , Athens, Greece
Leslie J. De Groot, MD
Dr De Groot trained at Columbia P & S Medical School, and did his Medical Residency at Presbyterian Hospital in NYC) and Massachusetts General Hospital in Boston. He served in the Public Health Service at National Institutes of Health in Bethesda for one year and in Afghanistan for a second year. He subsequently spent 12 years at Harvard and MGH in the Thyroid Study Unit, and directing the Clinical Research Center at MIT. He joined the Department of Medicine at Chicago in 1968. At U of C he was the head of the Thyroid Study Unit, and for many years Head of the Endocrine Section. He joined the Endocrine Division at Brown during 2004-2008, and is now on the faculty of University of Rhode Island, with a laboratory in Providence. Some of the honors received include Presidency of the American Thyroid Association, and Distinguished Service awards from the Endocrine Society and the Thyroid society. Research accomplishments include purification of thyroid peroxidase enzyme responsible for hormone synthesis and identifying it as the target antigen in thyroid autoimmunity, recognition of the Thyroid Hormone Resistance Syndrome and cloning the thyroid hormone receptor genes involved, identification of HLA DRA1*0501 and a CTLA-4 gene variant as important genetic factors in autoimmune thyroid disease, development of an adenoviral vector for therapy of medullary thyroid cancer, and numerous clinical studies on therapy of thyroid cancer and Graves’ disease. His research interests have recently centered on genetic mechanisms promoting auto-immune thyroid disease, definition of T cell epitopes in the TSH-Receptor antigen in Graves’ disease, and the role of regulatory T cells in the etiology of Graves’ disease. Having been a practicing thyroidologist for several decades, the final goal of his research is to use this information to develop methods to combat autoimmune disease in patients.
De Groot has more that four hundred publications, and received the Endocrine Society award as “Distinguished Educator” in 2004. Perhaps his best known publication is the three-volume textbook “ENDOCRINOLOGY” which he edited thru 6 editions over the past 30 years. He is currently committed to the educational possibilities of two web-books he directs, WWW.ENDOTEXT.ORG and WWW.THYROIDMANAGER.ORG, which receive over 80,000 hits each day from physicians around the world.
Associate Professor of Medicine at The Ohio State University Division of Endocrinology, Diabetes and Metabolism. Dr. Dungan attended medical school at OSU and completed her residency and fellowship in 2006 at University of North Carolina. She then returned to OSU where she serves as the division Associate Director of Clinical Services and the director of endocrine clinical trials, and oversees the inpatient diabetes program. She divides her time in clinical care and research in diabetes. Her research focuses on diabetes clinical trials, and ranges from quality improvement, pharmaceutical, and device interventions in the inpatient and outpatient settings. She has presented several times at national meetings such as the ADA and Endocrine Society and has published numerous manuscripts and chapters ranging from glucose monitoring, incretin based therapies, and insulins, to mechanistic and outcomes studies in hospitalized patients. She serves on the editorial board of Diabetes Technology & Therapeutics. She serves as the American Diabetes Association Central Ohio Community Leadership Board president and on the national ADA Scientific Sessions planning committee.
Kenneth R Feingold, MD
Professor of Medicine, University of California - San Francisco Staff Physician and Chief of the Endocrine Clinic - San Francisco VA Medical Center, Metabolism 111F, VA Medical San Francisco, CA 94121
Ashley Grossman, BA BSc MD FRCP FMedSci
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
Jerome Hershman, MD
Jerome M. Hershman, MD, MS, MACP is Distinguished Professor of Medicine at the David Geffen School of Medicine at UCLA, Associate Chief of the Endocrinology and Diabetes Division at the West Los Angeles VA Medical Center and Director of its Endocrine Clinic.
He was the Editor of the journal Thyroid from 1991-2000. He received a B.S. in chemistry from Northwestern University, a M.S. in chemistry from the California Institute of Technology, and a M.D. from the University of Illinois School of Medicine in Chicago. He was a resident in internal medicine at Beth Israel Hospital in Boston and the Boston VA Hospital and trained in endocrinology at the New England Medical Center. Dr. Hershman was a faculty member in the Department of Medicine at Northwestern University for 3 years, then at the University of Alabama in Birmingham for 5 years before moving to UCLA in 1972. He has authored over 340 research papers in endocrine literature and written more than 100 authoritative book chapters and reviews about thyroid function and disease. His current research focuses on the molecular biology of thyroid cancer and the management of thyroid diseases.
Christian A. Koch, MD, PhD
Professor with Tenure, Division of Endocrinology, Diabetes, Metabolism, Department of Medicine, University of Mississippi Medical Center,
Márta Korbonits, MD, PhD, DSc, FRCP
Prof. Márta Korbonits, MD, PhD, DSc, FRCP is a clinical academic endocrinologist. She graduated in medicine at Semmelweis Medical School in Budapest and works in the Department of Endocrinology at Barts and the London School of Medicine, where she is Co-Centre Head. She shares her time between clinical patient care, clinical research and laboratory based research as well as teaching at undergraduate and postgraduate level. Her current interests include endocrine tumorigenesis, especially the genetic origin of pituitary adenomas and she works on both the clinical characterisation as well as molecular aspects of this disease. She leads a large international consortium to study this issue. In addition, she focuses on translational research on the hormonal regulation of the metabolic enzyme AMP-activated protein kinase. She was a recipient of a Medical Research Council Clinician Scientist Fellowship, the Society for Endocrinology Medal, and the Endocrine Society Delbert Fischer award. She published over 200 papers and has an H index of 47 on Scopus. She is currently the Head of the Science Committee of the European Society of Endocrinology. She served on numerous Program Organising Committees for ECE, ENEA and SfE and was member of the executive board of the Society for Endocrinology, Pituitary Society and ENEA and European Society of Clinical Investigation. She is on the editorial board of Journal of Clinical Endocrinology and Metabolism and Pituitary and the endocrine editor of Scientific Reports and Annals of Human Genetics.
Robert McLachlan, MD
Professor Robert McLachlan is Director of Clinical Research at Prince Henry's Institute and Consultant Endocrinologist at the Monash Medical Centre in Melbourne, Australia. He is a physician-scientist having obtained a PhD in reproductive medicine from Monash University in 1987 and then he undertook a position as a Visiting Scientist at the
University of Washington, Seattle with Dr William Bremner in 1987-1989. Upon returning to Australia he has developed clinical and research interests in the fields of spermatogenesis, male fertility regulation and androgen physiology. He is Consultant Andrologist to the Monash IVF program with research interests in the genetics of male infertility. He has served as President of the Fertility Society of Australia and as Secretary of the International Society of Andrology, and is currently a consultant to the WHO on male fertility regulation. Since 2006, he has been Director of the Andrology Australia, a Federal Government initiative committed to research and community & professional education in male reproductive health. He has published more than 160 original papers and serves on editorial boards of leading endocrine and andrology journals, and as Editor of the Male Reproduction Section of www.ENDOTEXT.org .
Maria New, MD
Department of Pediatrics, Mount Sinai Medical School. New York, NY
Dr. Jonathan Q Purnell is a Professor of Medicine in the Oregon Health & Science University Knight Cardiovascular Institute and the Division of Endocrinology, and is the Associate Director of the Bob and Charlee Moore Institute for Nutrition and Wellness. He completed medical school at Oregon Health & Science University, Internal Medicine residency at the University of Vermont, and Endocrine Fellowship at the University of Washington under the mentorship of Dr. John Brunzell. His work as a physician scientist focuses on understanding the causes and consequences of obesity, metabolic syndrome, dyslipidemia, and diabetes in humans. Dr. Purnell is a member of the American Physiology Society, The Endocrine Society, The Obesity Society, The American Federation of Medical Research, and The American Diabetes Association.
Robert W. Rebar, M.D., is currently part-time Professor and Chair of the Department of Obstetrics and Gynecology at the new Western Michigan University Homer Stryker M.D. School of Medicine. He is the retired Executive Director of the American Society for Reproductive Medicine in Birmingham, Alabama, having served in that capacity from 2003 through 2013. Dr. Rebar is certified by the American Board of Obstetrics and Gynecology in obstetrics and gynecology and in reproductive endocrinology and infertility.
Dr. Rebar received his M.D. from the University of Michigan in 1972 and from 1972 to 1974 was a resident in obstetrics and gynecology at Parkland Memorial Hospital in Dallas, Texas. He was a Clinical Associate in the Reproduction Research Branch of the National Institute of Child Health and Human Development (1974-1976) before completing his residency in Obstetrics and Gynecology at the University of California at San Diego Medical Center (1976-1978). After his residency, Dr. Rebar continued on at the University of California, San Diego for six years (1978-1984), serving as Associate Professor and Director of the Division of Reproductive Endocrinology for the last two of those years. He was Professor and Head of the Division of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at the Northwestern University School of Medicine (1984-1988). Dr. Rebar then was Professor and Chairman of the Department of Obstetrics and Gynecology at the University of Cincinnati College of Medicine from 1988 through 1999 and served as Associate Executive Director of the American Society for Reproductive Medicine from 2000 through 2002.
Dr. Rebar is a member of numerous professional societies, including the American College of Obstetricians and Gynecologists (Fellow), the American Gynecological and Obstetrical Society, and the Society for the Study of Reproduction. Dr. Rebar has served on the editorial boards of several journals and is currently a Deputy Editor for the journal Contraception and an Associate Editor for Journal Watch Women’s Health and OB/GYN Clinical Alert. Dr. Rebar has contributed to many books, as well as authored over 250 articles on menopause, fertility, and reproductive endocrinology and has been the Principal or a Co-Investigator on several NIH grants.
Frederick Singer, MD
Frederick R. Singer, MD is Director of the Endocrine/Bone Disease Program at the John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California and is Clinical Professor of Medicine at UCLA School of Medicine.
Dr. Singer is past Chairman of the Board of Directors of the Paget Foundation and past president of the American Society for Bone and Mineral Research. He has served on many national public health committees, including as chairman of the USPHS FDA Endocrinologic Metabolic Drug Advisory Committee, on NIAMSD ad hoc review groups on osteoporosis, and as co-chairman of the NIAMSD National Research Plan Task Force on Bone Biology and Bone Diseases. He also was Chairman of the National Cancer Institute Special Study Section on Molecular Interactions Between Tumor Cells and Bone in 2003. Dr. Singer has served on the editorial boards of Calcified Tissue International, Journal of Bone and Mineral Research, Journal of Clinical Endocrinology and Metabolism, and Osteoporosis International, Dr. Singer received his MD degree from the University of California School of Medicine, San Francisco in 1963. He completed his postgraduate training in internal medicine at the University of California Affiliated Hospitals, Los Angeles, followed by research fellowships in endocrinology at the Royal Postgraduate Medical School, London and the Massachusetts General Hospital, Boston, Massachusetts. His research interests are skeletal complications of malignancy, Paget’s disease of bone, primary hyperparathyroidism, osteoporosis and the effect of vitamin D on breast cancer.
Dace Trence, MD
Dace L. Trence, MD, FACE is currently Director of the Diabetes Care Center and Associate Professor of Medicine at the University of Washington Medical Center in Seattle. She is also the University of Washington Endocrine Fellowship Program Director and Director of Endocrine Days, a medical education program for endocrinologists practicing in the Pacific Northwest. She currently serves on the American Association of Clinical Endocrinologists Board of Directors, chairing the AACE CME committee. She has been on the editorial boards of several journals including Clinical Diabetes. She has had articles published in JCEM, JAMA, Diabetes Care and is a co-author of Optimizing Diabetes Care for the Practitioner. Her current interests include improving educational processes in diabetes self management, clinical training of health care professionals, and vitamin D effects on glycemic control.
Aaron Vinik, MD
Dr Aaron Vinik is Professor of Medicine and Director of the Strelitz Diabetes Center, at Eastern Virginia Medical School, 855 West Brambleton Avenue, Norfolk, VA 23510 Email: email@example.com
Dr. Vinik has brought international recognition to Virginia as a result of his research and recent discovery of a gene, which could prove to be a cure for diabetes. The gene, INGAP (islet neogenesis associated protein) is responsible, either alone or in combination with other factors, for stimulating immature cells in the diabetic pancreas to produce insulin. When INGAP protein was administered to diabetic hamsters it was shown to reverse diabetes in 40% to 50% of animals. Animal studies were followed by human, multi-center clinical studies in both type 1 and type 2 diabetes, carried out by some of the most highly recognized investigators in the country; the results showed that even in type 1 diabetes an increase in C- peptide, (a measure of islet function), could be induced after 3 months of treatment. In type 2 diabetes, INGAP was able to stimulate an increase in C peptide and reduce HbA1c levels by close to 1%. Phase 2 clinical trials have been planned as multiple-center, randomized, double-blind, placebo-controlled studies to assess the safety, and efficacy of a new formulation of INGAP peptide given subcutaneously as injections for 12 weeks in adult patients with Type 1 diabetes, who have been treated with insulin for greater than 2 years and who are otherwise in good general health. The study locations for patients will be Montreal, Canada and Rochester, MN.
The discovery of INGAP has far reaching implications: it could free the two million people with type I diabetes from daily injections of insulin; it could help the 20 million people with type 2 diabetes whose pancreas ultimately fails; and, it could be used in genetic screening to identify those predisposed for developing diabetes. The discovery is a result of 16 years of perseverance, committed to the belief (thought by many to be heretical) that islets could be made to grow.
The success in finding the INGAP gene follows years of success in research and treatment of neuropathy, a complication of diabetes. Dr. Vinik is a national leader in basic and clinical neuropathy. He, in essence, has defined the heterogeneity of neuropathy, established a need for a modular approach depending on the particular nerve fiber damaged, and pioneered studies on the relationship between neuropathy, autoimmunity, and cell toxicity. He also pioneered the use of immunotherapy for autoimmune diabetic neuropathy. He has championed the evaluation of autonomic neuropathy as well as the identification of the site of pathology of diabetic peripheral neuropathy, using contact heat potentials (CHEPS). His advances in the understanding of neuropathy have resulted in patient treatment referrals from all parts of the United States and many other countries. He has been listed amongst the best physicians in USA for the past nine years.
Dr. Vinik has been invited to present his work all over the world. Recognized as a pioneer and a scholar, Dr. Vinik has authored six books, one devoted to islet regeneration, 109 book chapters, and has published more than 450 papers in peer-reviewed, highly reputable journals. He has also published more than 395 abstracts and he and the fellows he has trained have presented scientific papers at innumerable national and international meetings. He has been invited to give the Banting Lecture at the University of Toronto, the Minkowski Lecture in Kaunas, Lithuania, and the "INGAP Story" in Helsingor, Denmark at the International Pancreatic Islet Symposium. He has been "Meet the Professor" at the Endocrine Society, American Diabetes Association, and American College of Physicians. Dr. Vinik received the award for the Virginia Outstanding Scientist by the Science Museum of VA, in 2002 and the Southern Medical Association’s Seale Harris Award in 2003. He received the Dean's Award for Outstanding Research in 1993 and the Dean's Award for Outstanding Faculty in 1999.
He was awarded Alpha Omega Alpha in 2004 by students of EVMS. In 2005, he was elected to Mastership of the American College of Physicians.
Dr. Vinik is a member of a number of professional societies including the American Endocrine, Diabetes, Gastroenterology, and the European and International Diabetes associations. Dr. Vinik served as a member of the National Institute of Health General Clinical Research Center Study Section and the NIH Data Management committee. He was also Chairman of the American Diabetes Association task force on Nutrition, which established the guidelines for nutritional management of diabetes, and Chairman of the subcommittee for development of guidelines for neuropathy testing; in addition, he was a member of the committee to develop guidelines for managing lipid disorders in diabetes. He has served previously as Chairperson of the American Diabetes Association Grant Review Committee and as Director of the National Post-Graduate Education Course.
Dr. Vinik’s scholarly pursuits include reviewing scientific manuscripts for many journals. Additionally, he is Editor of “Endocrine Reviews” and Associate Editor of “Diabetes Care;” He is also an editor of several books, such as “Neuroendocrine Tumors” from Interscience Institute; editor of the section on Neuroendocrine Tumors in De Groot’s textbook of Endocrinology; of the section on Neuroendocrine Tumors in the textbook, Cancer Medicine, and co-editor of the textbook, “Controversies in Treating Diabetes.”
Dr Vinik is a featured speaker on diabetic neuropathy in the television series, D-Life, which presents education programs on diabetes to the public.
Dr. Vinik has received research funding for his studies from the National Institutes of Health, the National Cancer Institute, the Kroc Foundation, the American Diabetes Association, HUD, DHHS, NASA, The Diabetes Institutes Foundation, and pharmaceutical industries.
Dr. Vinik holds three issued patents and six more patents are being studied. He holds the copyright for the Norfolk Quality of Life tool, used as an end-point for clinical trials in neuropathy for assessing lifestyle problems in patients with diabetic neuropathy. He also holds the copyright for the questionnaire for assessing Quality of Life in patients with neuroendocrine tumors.